000			02717cam a2200373 i 4500
001			2018000263
003			DLC
005			20190716140233.0
008			180316s2018 nyu b 001 0 eng
010			_a 2018000263
020			_a9781524731656 (hardback)
042			_apcc
043			_an-us---
040			_aDLC _beng _erda _cDLC
050	0	0	_aHD9995.H423 _bU627 2018
082	0	0	_a338.7/681761 _223
084			_aBUS025000 _aBUS027000 _aTEC059000 _2bisacsh
100	1		_aCarreyrou, John,
245	1	0	_aBad blood : _bsecrets and lies in a Silicon Valley startup / _cJohn Carreyrou.
264		1	_aNew York : _bAlfred A. Knopf, _c2018.
300			_ax, 339 pages ; _c25 cm
336			_atext _btxt _2rdacontent
337			_aunmediated _bn _2rdamedia
338			_avolume _bnc _2rdacarrier
504			_aIncludes bibliographical (pages 305-324) and index.
520			_a"The full inside story of the breathtaking rise and shocking collapse of Theranos--the Enron of Silicon Valley--by the prize-winning journalist who first broke the story and pursued it to the end in the face of pressure and threats from the CEO and her lawyers. In 2014, Theranos founder and CEO Elizabeth Holmes was widely seen as the female Steve Jobs: a brilliant Stanford dropout whose startup "unicorn" promised to revolutionize the medical industry with a machine that would make blood tests significantly faster and easier. Backed by investors such as Larry Ellison and Tim Draper, Theranos sold shares in an early fundraising round that valued the company at $9 billion, putting Holmes's worth at an estimated $4.7 billion. There was just one problem: the technology didn't work. For years, Holmes had been misleading investors, FDA officials, and her own employees. When Carreyrou, working at the Wall Street Journal, got a tip from a former Theranos employee and started asking questions, both Carreyrou and the Journal were threatened with lawsuits. Undaunted, the newspaper ran the first of dozens of Theranos articles in late 2015. By early 2017, the company's value was zero and Holmes faced potential legal action from the government and her investors. Here is the riveting story of the biggest corporate fraud since Enron, a disturbing cautionary tale set amid the bold promises and gold-rush frenzy of Silicon Valley"-- _cProvided by publisher.
610	2	0	_aTheranos (Firm) _xHistory.
650		0	_aHematologic equipment industry _zUnited States.
650		0	_aFraud _zUnited States.
650		7	_aBUSINESS & ECONOMICS / Entrepreneurship. _2bisacsh
650		7	_aBUSINESS & ECONOMICS / Finance. _2bisacsh
650		7	_aTECHNOLOGY & ENGINEERING / Biomedical. _2bisacsh
999			_c233935 _d233935